The role of microRNAs in liver cancer

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 3, 2012, Pages 223-228

  Papaconstantinou, Ioannis ^a   Karakatsanis, Andreas ^a   Gazouli, Maria ^b   Polymeneas, George ^a   Voros, Dionissios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cholangiocarcinoma; hepatocellular carcinoma; microRNAs

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MICRORNA; MICRORNA 101; MICRORNA 10B; MICRORNA 122; MICRORNA 125B; MICRORNA 126; MICRORNA 148A; MICRORNA 18; MICRORNA 181; MICRORNA 199 A 5P; MICRORNA 20; MICRORNA 203; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 224; MICRORNA 26; MICRORNA 26A; MICRORNA 30C 1; MICRORNA 34A; MICRORNA 92; MICRORNA 96; UNCLASSIFIED DRUG;

ABDOMINAL RADIOGRAPHY; ALCOHOL LIVER DISEASE; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RELAPSE; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DOWN REGULATION; FATTY LIVER; GENE EXPRESSION; GOLD STANDARD; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PARENCHYMA; LIVER RESECTION; LIVER TRANSPLANTATION; NONHUMAN; OVERALL SURVIVAL; PORTAL VEIN; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE RISK; REVIEW; SURGICAL TECHNIQUE; SYSTEMIC THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VOLUME; UPREGULATION;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; EARLY DIAGNOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MICRORNAS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 84856743526     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283505063     Document Type: Review

References (72)

1. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248:84-96.
2. Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA 2005; 55:74.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442. (Pubitemid 36152543)
4. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol2005; 11:7391-7400. (Pubitemid 43126017)
5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699. (Pubitemid 26079803)
6. Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008; 15:1001-1007.
7. Lang H, Sotiropoulos GC, Fruhauf NR, Domland M, Paul A, Kind EM, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005; 241:134-143. (Pubitemid 40041002)
8. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69:1633-1637.
9. Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocar cinoma. Transpl Int2010; 23:692-697.
10. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl2004; 10:S115-S120. (Pubitemid 38240111)
11. Shaib Y, El-Serag HB. The epidemiology of cholangiocar cinoma. Semin Liver Dis 2004; 24:115-125.
12. Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ, Hassan MM. Riskfactors for intrahepatic and extrahepatic cholangiocar cinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102:1016-1021. (Pubitemid 46698225)
13. Blechacz B, Gores GJ. Cholangiocar Cinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48:308-321. (Pubitemid 351975555)
14. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, etal. Therapeutic delivery of mi R-26a inhibits cancer cell proliferation and induces tumor-specific apoptosis. Cell 2009; 137: 1005-1017.
15. Kiss T. Small nucleolar RNAs: an abundant group of noncoding RNAs with diversecellularfunctions. Cell 2002; 109:145-148. (Pubitemid 34518252)
16. Bartel DP. Micro RNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
17. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-854. (Pubitemid 24014542)
18. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, etal. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403:901-906. (Pubitemid 30130993)
19. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. mi RBase: tools for micro RNA genomics. Nucleic Acids Res 2008; 36:D154-D158. (Pubitemid 351149713)
20. Lee Y,Ahn C, Han J, Choi H, Kim J,Yim J, etal. The nuclear RNase III Drosha initiates micro RNA processing. Nature 2003; 425:415-419. (Pubitemid 37187272)
21. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human micro RNAs. Nat Struct Mol Biol 2006; 13:1097-1101. (Pubitemid 44885920)
22. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. Micro RNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23:4051-4060. (Pubitemid 39472426)
23. Esquela-Kerscher A, Slack FJ. Oncomirs: micro RNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-269.
24. Li M, Marin-Muller C, Bharadwaj U, Chow KH,Yao Q, Chen C. Micro RNAs: control and loss of control in human physiology and disease. World J Surg 2009; 33:667-684.
25. Chen XM. Micro RNA signatures in liver diseases. World J Gastroenterol 2009; 15:1665-1672.
26. Bala S, Marcos M, Szabo G. Emerging role of micro RNAs in liver diseases. World J Gastroenterol 2009; 15:5633-5640.
27. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of micro RNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25:2537-2545.
28. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, et al. Association of micro RNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14:419-427. (Pubitemid 351226109)
29. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. Micro RNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellularcancer. Gastroenterology 2007; 133:647-658. (Pubitemid 47187346)
30. Huang YS, Dai Y, Yu XF, Bao SY, Yin YB, Tang M, Hu CX. Microarray analysis of micro RNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol 2008; 23:87-94. (Pubitemid 350265207)
31. Wang Y, Lee A, Ma J, Wang J, Ren J, Yang Y, et al. Profiling micro RNA expression in hepatocellular carcinoma reveals micro RNA-224 up-regulation and apoptosis inhibitor-5 as a micro RNA-224-specific target. J Biol Chem 2008; 283:13205.
32. Li W, Xie L, He X, Li J, Tu K, Wei L, et al. Diagnostic and prognostic implications of micro RNAs in human hepatocellular carcinoma. Int J Cancer 2008; 123:1616-1622.
33. Su H, Yang J, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM. Micro RNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69:1135.
34. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu C, et al. Cyclin G1 is atarget of mi R-122a, a micro RNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67:6092.
35. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, et al. Downregulation of mi R-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99:671-678. (Pubitemid 44521987)
36. Jopling C, Norman K, Sarnow P. Positive and negative modulation of viral and cellular m RNAs by liver-specific micro RNA mi R-122. Cold Spring Harb Symp Quant Biol 2006; 71:369-376.
37. Randall G, Panis M, Cooper JD,Tellinghuisen TL, Sukhodolets KE, Pfeffer S, et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci USA 2007; 104:12884-12889. (Pubitemid 47255249)
38. Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL. mi R-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2008; 375:315-320.
39. Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, et al. Upregulation of mi R-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer 2008; 123:972-978. (Pubitemid 352032429)
40. Connolly E, Melegari M, Landgraf P,Tchaikovskaya T,Tennant BC, Slagle BL, etal. Elevated expression of the mi R-17-92 polycistron and mi R-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008; 173:856-864.
41. Fornari F, Gramantieri L, Ferracin M,Veronese A, Sabbioni S, Calin GA, etal. Mi R-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27:5651-5661.
42. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, et al. Micro RNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 2009; 136:683-693.
43. Xu T, Zhu Y, Wei Q, Yuan Y, Zhou F, Ge Y, et al. A functional polymorphism in the mi R-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 2008; 29:2126.
44. Li S, Fu H, Wang Y, Tie Y, Xing R, Zhu J, et al. Micro RNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology 2009; 49:1194-1202.
45. Calin GA, Croce CM. Micro RNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-866. (Pubitemid 44629897)
46. Asselah T, Bieche I, Sabbagh A, Bedossa P, Moreau R, Valla D, et al. Gene expression and hepatitis C virus infection. Gut 2009; 58:846-858.
47. Cheung O, Puri P, Eicken C, Contos M, Mirshahi F, Maher J, et al. Nonalcoholic steatohepatitis is associated with altered hepatic micro RNA expression. Hepatology 2008; 48:1810-1820.
48. Ura S, Honda M,Yamashita T, Ueda T,Takatori H, Nishino R, etal. Differential micro RNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49:1098-1112.
49. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. Micro RNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47:1223-1232. (Pubitemid 351547908)
50. Ladeiro Y, Couchy G, Balabaud C, Bioulac Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. Micro RNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47:1955-1963. (Pubitemid 351952843)
51. Wong Q, Lung R, Law P, Lai P, Chan K, To K, Wong N. Micro RNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression ofstathmin1. Gastroenterology 2008; 135:257.
52. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, et al. Methylation mediated silencing of micro RNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008; 68:5049-5058.
53. Yang J, Zhou F, Xu T, Deng H, Ge YY, Zhang C, et al. Analysis of sequence variations in 59 micro RNAs in hepatocellular carcinomas. Mutat Res 2008; 638:205-209.
54. Shen Q, Cicinnati VR, Zhang X, Iacob S, Weber F, Sotiropoulos GC, et al. Role of micro RNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer 2010; 9:227.
55. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. mi R-34a inhibits migration and invasion by downregulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 2009; 275:44-53.
56. Gramantieri L, Fornari F, Ferracin M,Veronese A, Sabbioni S, Calin GA, etal. Micro RNA-221 Targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009; 15:5073-5081.
57. Ji J, Yamashita T, Budhu A, Forgues M, Jia H, Li C, et al. Identification of micro RNA 181 by genome wide screening as a critical player in Ep CAM-positive hepatic cancer stem cells. Hepatology 2009; 50: 472-480.
58. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, etal. Identification of metastasis-related micro RNAs in hepatocellular carcinoma. Hepatology 2008; 47:897-907. (Pubitemid 351449681)
59. Ji J, Wang XW. New kids on the block: diagnostic and prognostic micro RNAs in hepatocellular carcinoma. Cancer Biol Therap 2009; 8:1686-1693.
60. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Calin GA, et al. Mi R-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69:5761-5769.
61. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. Micro RNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361:1437-1447.
62. Alpini G, Mc Gill JM, Larusso NF. The pathobiology of biliary epithelia. Hepatology 2002; 35:1256-1268. (Pubitemid 34454023)
63. Sirica AE. Cholangiocar Cinoma: moleculartargeting strategies for chemoprevention and therapy. Hepatology 2005; 41:5-15. (Pubitemid 40066375)
64. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, et al. Involvement of human micro RNA in growth and response to chemotherapy in human cholangiocar cinoma cell lines. Gastroenterology 2006; 130:2113-2129. (Pubitemid 43816961)
65. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The micro RNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 2007; 282:8256-8264. (Pubitemid 47093612)
66. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epigenetic regulation of micro RNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008; 27:378-386.
67. Mott JL, Kobayashi S, Bronk SF, Gores GJ. Mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26:6133-6140. (Pubitemid 47414372)
68. Kawahigashi Y, Mishima T, Mizuguchi Y, Arima Y,Yokomuro S, Kanda T, etal. Micro RNA profiling of human intrahepatic cholangiocar cinoma cell lines reveals biliary epithelial cell-specific micro RNAs. J Nippon Med Sch 2009; 76:188-197.
69. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al. Postoperative interferon alphatreatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132:458-465.
70. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245:831-842. (Pubitemid 46809282)
71. Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg 2007; 245:843-845.
72. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.